Pay in 4 interest-free payments of $6.20 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Component-Level Trial Findings CJC-1295 (without DAC, modified GRF 1-29) Phase 1 and Phase 2 work described: Dose-dependent GH elevation (2-10x baseline at studied doses, PMID 16352683) IGF-1 elevation of 1.5-3x baseline at 1-2 weeks Mild facial flushing post-injection in some participants No serious adverse events at studied doses CJC-1295 with DAC The DAC-modified version covalently binds to albumin, extending half-life to 5-8 days (PMID 16352683)
Bull Exp Biol Med 165:746750 Fernley HN (1971) Mammalian alkaline phosphatases Enzymes 4:417447 Foley MH, OFlaherty S, Barrangou R et al (2019) Bile salt hydrolases: gatekeepers of bile acid metabolism and host-microbiome crosstalk in the gastrointestinal tract
What If You Feel Nauseous
From 2017-18 to 2021-23, the share of adults considered obese declined by around 2 percentage points
